UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 109

of 'Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials'

109
TI
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
AU
Guo Y, Xiong BH, Zhang T, Cheng Y, Ma L
SO
Cancer Invest. 2016 Feb;34(2):94-104. Epub 2016 Feb 11.
 
This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included. A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group. For mCRC, the effect of XELOX is similar to FOLFOX.
AD
a Department of Gastrointestinal Surgery , First Affiliated Hospital of Chongqing Medical University , Chongqing , China.
PMID